Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells
- 5 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 121 (3), 539-553
- https://doi.org/10.1007/s10549-009-0492-0
Abstract
Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90-fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≦1 year, *P < .009). We also found that higher-expressing ENO-1 tumors confer longer distance relapse (tumor/normal ratio = 82.8–92.4-fold) when compared to locoregional relapse (tumor/normal ratio = 43.4-fold) in postsurgical 4-hydroxy-tamoxifen (4-OHT)-treated ER+ patients (*P = .014). These data imply that changes in tumor ENO-1 levels are related to clinical 4-OHT therapeutic outcome. In vitro studies demonstrated that decreasing ENO-1 expression using small interfering RNA (siRNA) significantly augmented 4-OHT (100 nM)-induced cytotoxicity in tamoxifen-resistant (Tam-R) breast cancer cells. These results suggest that downregulation of ENO-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy.Keywords
This publication has 46 references indexed in Scilit:
- Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cellsJournal of Molecular Endocrinology, 2008
- Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cellsFree Radical Biology & Medicine, 2008
- Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen ReceptorCancer Research, 2008
- Beyond tamoxifen: Extended and late extended endocrine therapy in postmenopausal early breast cancerCancer Treatment Reviews, 2008
- ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cellsEndocrine-Related Cancer, 2008
- Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancerBiomedicine & Pharmacotherapy, 2007
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- A new screening system for proliferation-independent anti-cancer agentsCancer Letters, 2004
- Use of tamoxifen for breast cancer: twenty-eight years later.Journal of Clinical Oncology, 1995
- Crystal structure of enolase indicates that enolase and pyruvate kinase evolved from a common ancestorNature, 1988